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ABSTRACT 
Background: 
Hemodynamic responses of laparoscopy should be attenuated by the appropriate 
premedication. The present study evaluated the clinical efficacy of oral premedication 
with Clonidine 200 µg or Pregabalin 150 mg for hemodynamic stability during 
laparoscopic surgeries. 
Methods: 
A total of 90 healthy adult patients aged 18 to 60 years with ASA physical status I 
& II of both gender, who met the inclusion criteria for elective laparoscopic surgeries, 
were randomized to receive Placebo Group I, Clonidine 200 µg Group II, or Pregabalin 
150 mg, given 60 minutes before surgery as oral premedication. All groups were 
compared for heart rate, systolic blood pressure, diastolic blood pressure and mean 
arterial pressure prior to premedication, before induction, after intubation 1 and 5 
minutes, after pneumoperitoneum 1,5,15,30 & 45 minutes, after pneumoperitoneum 
release, and after extubation. Intraoperative analgesic requirement, post operative 
sedation ,pain scale and complications were also recorded. 
Results: 
Both Clonidine and pregabalin were effective in producing intra operative 
hemodynamic stability as compared to the control group by blunting the stress response 
to pneumoperitonium but the hemodynamic stability is better with clonidine group than  
pregabalin group, which itself is better than placebo group. 
 The pain scores was significantly reduced in clonidine and pregabalin groups when 
compared to the placebo group but the reduction in scores in the pregabalin group is 
significantly less than that of the clonidine group.  
The sedation score is higher in clonidine group when compared to placebo and 
pregabalin. 
Intraoperative fentanyl requirement is more with placebo group than pregabaline  
group , which itself  higher than clonidine group. 
Drowsiness is more with clonidine group than pregabalin and placebo. 
Post operative nausea and vomiting incidence was similar in all groups. 
Conclusion: 
This study concluded that oral premedication with Clonidine 200 µg and 
Pregabalin 150mg produces better hemodynamic stability in laparoscopic surgeries but 
Clonidine produces better haemodynamic stability than Pregabalin .Both drugs has 
significantly reduces intraoperative and post operative analgesic requirements without 
significant post operative respiratory depression. 
  
Key words: 
 Haemodynamic response, laparoscopic surgeries, Clonidine, pregabalin, 
Pneumaperitoneun,   
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INTRODUCTION 
Visualization of abdominal cavity through an endoscope is called as 
Laparoscopy.   Laparoscopic surgeries are now become the “gold standard” of 
many surgical procedures including inguinal hernias. But this procedure is not 
free of risk.  It produces very significant haemodynamic changes, which are 
usually transient in nature and unpredictable and these changes are very well 
tolerated by normal patients but may be dangerous in patients with heart disease 
and COPD.   
Pneumoperitoneum affects several homeostatic systems leading to 
alterations in cardiovascular, lung physiology and stress response. 
 The cardiac changes associated with pneumoperitoneum are an increasein 
mean arterial pressure reduction in cardiac output and increase in systemic 
vascular resistance which leads reduction in tissue perfusion.   
Hence many drugs were used to prevent haemodynamic changes 
associated with pneumoperitoneum. To correct the reduction of cardiac output 
seen with raised pulmonary occlusion pressure and systemic vascular resistance 
Nitroglycerine was commonly used. 
Clonidine helps in modulating the haemodynamic changes induced by 
pneumoperitoneum by inhibiting the release of catecholamine and vasopressin . 
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Pregabalin by binding to the calcium channels, modulates the release of several 
excitatory neurotransmitters like norepinephrine, substanceP, glutamate and 
calcitonin gene – related peptide. 
The present study was designed to evaluate the extent of haemodynamic 
changes associated with laparoscopic surgery and also to compare the effects of 
oral Clonidine and Pregabalin in prevention of  haemodynamic changes.  
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AIM AND OBJECTIVES OF THE STUDY 
 
PRIMARY OBJECTIVE  
To compare the effectiveness of oral Clonidine and oral Pregabalin for 
hemodynamic stability during laparoscopic surgeries. 
SECONDARY OBJECTIVES  
To determine 
 The additional  analgesic requirement 
 The postoperative complications  namely nausea, vomiting  and 
drowsiness  
 Post operative pain and sedation.                                                
LAPAROSCOPIC SURGERY 
Laparoscopic surgeries are very commonly done worldwide. Compared to 
an open procedure laparoscopy has many advantages like less surgical trauma, 
less stress response to operative procedure, less intraoperative and postoperative 
pain, early return of gastrointestinal function, better postoperative lung function 
and hence early discharge. For the patient minimal wound infection andabove all 
better cosmetic result.  
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The technique of laparoscopy involves insufflation of gas mostly 
carbondioxide into peritoneal cavity to separate the organs from abdominal wall 
by the creation of a pneumoperitonium. The gas insufflation is done by a 
specialised VERESS needle, at an initial rate of 2-4 lit /minute and pressure of 
12-15 mm of Hg. Later the pneumoperitoneum is maintained by a gas flow at a 
constant rate of 200-400 ml/min. 
 Due to pneumoperitoneum intraoperative problems during laparoscopic 
surgery1 can be cardiovascular, respiratory,renal, gastrointestinal or metabolic 
related. The main cardiovascular problems are decrease in venous return, reflex 
tachycardia and arrhythmias. Respiratory problems are due to cephalad 
displacement of diaphragm. It result in reduction of functional residual capacity, 
compliance by 30-50%.  There is a rise in airway resistance in obese patients and 
persons with cardiopulmonary disease. Develpoment of atelectasis and 
intrapulmonary shunting leading to hypoxemia. Hypercarbia may also result 
from CO2 absorption from pneumoperitonium. For this reason ETCO2 (End tidal 
CO2) monitoring is mandatory during laparoscopic surgeries.  
Gastric regurgitation and aspiration are possible due to increased intra 
abdominal pressure. The instruments introduced into the abdomen may cause 
injuries to the visceral organs. Insertion of Trocharcan damage viscera; more 
likely a distended stomach usually by mask ventilation. Due to residual 
pneumoperitoneum there is increased incidence of nausea and vomiting after 
5 
 
laparoscopic procedure. Renal function and urine output are affected when the 
intra-abdominal pressure rises >20mmHg. Renal blood flow and glomerular 
filtration rate decreases as a result of increase in renal vascular resistance, 
reduction in glomerular filtration gradient and decrease in cardiac output. Other 
respiratory complications of gas insufflation are subcutaneous emphysema, 
pneumomediastinum, pneumopericardium, pneumothorax and venous gas 
embolism. In the preanaesthetic checkup, cardiac and respiratory function is 
assessed carefully. General anaesthesia with controlled ventilation2 is the most 
common method. Ventilatory pattern is adjusted according to respiratory and 
hemodynamic response of the patient. Large tidal volumes (12-15ml/kg) prevent 
progressive microatelectasis and hypoxemia and allows for more effective 
alveolar ventilation and CO2 elimination. However peak airway pressure is 
monitored to check excessive increase. Preferred volatile anaesthetic of choice is 
Isoflurane because it causes less myocardial depression and is less 
arrhythmogenic. 
 Pain consists of vague abdominal and shoulder discomfort while the Pain 
from trocharpuncture wounds are usually mild. 
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Hemodynamic Problems During Laparoscopy 1,3 
 Hemodynamic changes during laparoscopy results as a consequence of 
pneumoperitoneum, hypercapnia, anaesthesia, and patient position. In addition 
there is a reflex increase of vagal tone and arrhythmias can also occur.  
Peritoneal insufflation to IAP higher than 15 mm Hg induces significant 
hemodynamic alterations. These disturbances are characterized by fall in cardiac 
output, rise in arterial pressures and elevation of both systemic and pulmonary 
vascular resistances. Heart rate remains unchanged or increased only slightly. 
The decrease in cardiac output is proportional to the increase in IAP. 
Cardiac output which decrease shortly after the beginning of the 
peritoneal insufflation, subsequently increase, probably as a result of surgical 
stress.  
 The mechanism of the decrease of cardiac output is multifactorial. 
Increased IAP results in venacaval compression, pooling of blood in the legs, and 
an increase in venous resistance.The decline in venous return, which parallels the 
decrease in cardiac output, is confirmed by a reduction in left ventricular end-
diastolic volume measured using transesophageal echocardiography. Increase in 
cardiac filling pressures during peritoneal insufflation can be explained by the 
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increased intrathoracic pressure associated with pneumoperitoneum. During 
pneumoperitoneum, right atrial pressure and pulmonary artery occlusion pressure 
can not be considered as reliable indices of cardiac filling pressures. Abdominal 
insufflation interferes with venous return as suggested by the fact that atrial 
natriuretic peptide concentrations remain low despite increased pulmonary 
capillary occlusion pressure during pneumoperitoneum. By increasing circulating 
volume beforethe pneumoperitoneum can improve the venous return and cardiac 
output.  Fluid loading or tilting the patient to a slight head-down position before 
peritoneal insufflations increases filling pressures. 
 Echocardiography studies have shown that the ejection fraction of the left 
ventricle, does not appear to decrease significantly when IAP increases to 15 mm 
Hg. However, all studies show an increase in systemic vascular resistance during 
the pneumoperitoneum.Although the normal heart tolerates rise in afterload 
within physiologic limits, the increases in afterloadproduced by 
pneumoperitoneum can be deleterious to patients with cardiopulmonary disease. 
There is a relation between increase in systemic vascular resistance and 
patient position. The head-up position aggravates while the trendelenburg 
position attenuates the increase. By the administration of vasodilators like 
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nitroglycerin or nicardipine or volatile anesthetics like isoflurane, the increase in 
systemic vascular resistance can be corrected.  
 Both mechanical and neurohumoral factors raise the systemic vascular 
resistance.  The involvement of neurohumoral factor is suggested by the gradual 
return of hemodynamic parameters to baseline values. In the presence of the 
pneumoperitoneum the levels of catecholamines, the renin-angiotensin system 
and especially vasopressin rises which increases the afterload. Peritoneal 
receptors are mechanically stimulated which results in increased vasopressin 
release, rise in systemic vascular resistance and arterial pressure. The rise in 
systemic vascular resistance also explains fall in cardiac output inspite of 
increase in arterial pressure.Use of centrally acting α2-adrenergic agonist drugs 
like clonidine or dexmedetomidine and β-blocking agents like metoprolol 
drastically reduces hemodynamic changes and requirement of anaesthetic 
medications. Recent studies show the use of remifentanil in higher doses almost 
completely prevents the hemodynamic changes.  
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PHARMOCOLOGY OF CLONIDINE HYDROCHLORIDE1,16 
Clonidine hydrochloride was introduced in early 1960s, as a nasal 
decongestant then its anti- hypertensive property was found out. Later on based 
on itspharmacological properties  it  is used in clinical anaesthesia. 
 
Figure  1.  Clonidine Hydrochioride 
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          Clonidine hydrochloride is an “imidazoline” compound and exists as a 
mesomeric compound. The chemical name : 2-(2, 6- dichlorophenylamino)-
2imidazoline hydrochloride. The structural formula is “ C9H9C12N3HCl”.  
        The molecular wt is 266.56. Clonidine is an odourless, bitter, white, 
crystalline substance, soluble in both alcohol and water. Clonidine improves the 
quality of anaesthesia, provides intraoperative cardiovascular stability during 
surgery and decreases anaesthetic requirement. Clonidine may reduce the MAC 
value of volatile agents like halothane  upto 50% in a dose dependent manner.  In 
peripheral nerve blocks and central neuraxial blockade,Clonidine potentiatesthe 
anaesthetic action of the local anaesthetics with less side effects.  
Availability:    
 Available as tablets in following strength:  
100 microgram, 200 microgram and 300 micrograms.  
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Mechanism of action:  
Clonidine is a centrally acting partial α2 adrenergic agonist with a 
selectivity ratio of 220: 1 in favour of α2 receptors.  The α2 receptors are of three 
subtypes:α2a, α2b, α2c.   
Sedation, analgesia and sympatholysis are mediated by α2a receptors . α2b 
receptors are responsible for  vasoconstriction and anti- shivering.  α2c receptors 
are responsible for the startle response.  Epidurally injected clonidine reaches the 
hypothalamus and medulla, by crossing the blood brain barrier as it is lipid 
soluble.  It reduce the central neural transmission in the spinal neurons 
bystimulating the inhibitory α2adrenoreceptors.The analgesic effect is due to 
inhibition of substance- P release. 
The α2 adrenoreceptors are located on the afferent neurons in the 
superficial laminae of the spinal cord and in several brain stem nuclei implicated 
in analgesia.  The superficial laminae contain 3 group of neurons :1. tonic,2. 
adapting, 3.single- spike firing.They receive their primary sensory input from Aδ 
and C fibres. Analgesic effect of clonidine due to the release of acetylcholine in 
the neuraxial region and  inhibition of  voltage gated Na+ and K+ channels which 
suppresses the generation of action potentials in tonic- firing spinal dorsal horn 
neurons. Sedation is due to its action on locus ceruleus.  
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Clonidine has opposing action at multiple sites after neuraxial or systemic 
administration .It therefore affects the systemic blood pressure in a complex 
manner.  It reduces sympathetic drive by acting on the nucleus tractus solitarius 
and locus ceruleus of the brain stem through activation of post- synaptic α2 
adrenoreceptors. It also activates nor-adrenergic imidazoline preferring binding 
sites in the lateral reticular nucleus producing hypotension and anti- 
arrythmogenic action. In the periphery it acts on pre-synaptic α2 adrenoreceptors 
at sympathetic terminals and decreases the release of nor-epinephrine causing 
vasorelaxation and reduced chronotropic drive. The brainstem and the peripheral 
effects of α2 adrenoreceptor activation are counterbalanced by the direct 
peripheral vasoconstriction through its action on α2adrenoreceptors from the 
circulating concentrations of clonidine.    The dose response curve for clonidine 
by neuraxial or systemic administration is U-shaped, with peripheral 
vasoconstriction from circulating drug concentrations at high doses opposing 
central sympatholysis.  
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Pharmacodynamics:  
The analgesic effect of clonidine is more potent after neuraxial 
administration than systemicadministration. 
Cardiovascular system:   
Clonidine has minimal effects on responses to vasoconstrictors or 
anticholinergics given to treat hypotension or bradycardia respectively that may 
occur in neuraxial anaesthesia.  
Sedation: 
Clonidine produces sedation at the dose of 50 micrograms or more in less 
than 20 minutes. Sedation is dose dependent and irrespective of the route of 
administration.  
Respiration:   
Clonidine doesn’t produce respiratory depression even after massive 
overdose.They do not potentiate respiratory depression from opioids.  
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Peripheral nerves:    
 At high concentrations a minor degree of blockade is noted with some 
preference for C- fibres in the peripheral nerves. It therefore enhance the 
peripheral nerve block when added with local anaesthetics due to the absence of   
α2adrenoreceptors on the axons of peripheral nerves.    
Pharmacokinetics: 
          Oral Clonidine has nearly 90% bio availability because of its good oral 
absorption. The mean half-life of the drug in plasma is about 10 - 12 hours. 70% 
of drug is excreted in an unchanged form by the kidney, and its half- life 
increases in renal failure and hence dose adjustment to be done. 
In transdermal route drug is released at a constant rate for a week. Steady state 
concentration achieved by 72 hours. 
Because of its high lipid solubility, it rapidly distributes into extra- vascular sites 
including the central nervous system.    
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Distribution t ½  : 11 ± 9 minutes.  
Elimination t½  : 9 ± 2 hour,  41 hours in severe renal  
dysfunction.  
Volume of distribution :  2.1 ± 0.4 l/kg  
Plasma protein binding  :  22 - 40%.  
Metabolism    :  Minor pathways with the major   
metabolite is  P- OH clonidine 
 Excretion:   
70% of the dose, mainly in the form of unchanged parent drug  in urine.  
So, the elimination t½ of clonidine varies as a function of creatinine clearance.  In 
subjects undergoing hemodialysis only 5% of the body clonidine store was 
removed.  
Adverse effects:   
1. General:  Weakness, fatigue, headache and withdrawal syndrome, 
pallor. 
2. Cardiovascular: palpitations, tachycardia, bradycardia about 5 in 1000  
syncope, raynaud’s phenomenon, congestive cardiac failure, ECG 
abnormalities like sinus node arrest, junctional rhythm, AV block and 
arrhythmias are reported.   
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3. Central nervous system: nervousness, agitation, mental depression, 
insomnia, vivid dreams or night mares. 
4. Dermatological: rash, angioneurotic edema, pruritus, urticaria and 
alopecia.  
5. Gastro intestinal tract: nausea and vomiting, anorexia, malaise, transient 
abnormalities in liver function tests, hepatitis. 
6. Genitourinary: in chronic intake leads to decreased sexual activity, 
impotence, loss of libido, nocturia.  
7. Hematologic: thrombocytopenia rarely.  
8. Metabolic: weight gain and gynaecomastia 
9.   Musculoskeletal: muscle pain, joint pain and leg cramps.  
10. Ear, nose and throat:  Nasal mucosa dryness.  
11. Opthalmological: dryness, burning of eyes.  
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Precautions: 
1. In renal insufficiency patient , dose reduction needed.   
2. Sudden withdrawal produces hypertensive crisis. So it should be 
gradually discontinued over 2 to 4 days.  
3. Use with caution in patients with cerebrovascular or coronary 
insufficiency.  
4. Intrathecal / epidural clonidine often causes bradycardia that if 
symptomatic can be treated with inj. Atropine.  
Contraindications:  
1. History of hypersensitivity to clonidine or its components.   
2. In patients with bradyarrhythmia or AV block.  
3. Patients with severe cardiovascular disease  
4. Patients with cardiovascular / hemodynamic instability.  
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Interactions: 
1. Clonidine potentiates the CNS- depressant drugs like alcohol, barbiturates 
and  other sedatives.  
2. Narcotics  potentiate the hypotensive effects of clonidine,  
While tricyclic anti depressants antagonize  hypotensive effects.  
3. Co-administration of drugs with a negative chronotropic drugs such as beta 
blockers, digoxin can  potentiate bradycardiac rhythm disturbances.  
4. Beta blockers may potentiate the hypertensive responses produced by 
clonidine withdrawal.  
Indications:  
1. To prolong the duration of epidural/ spinal anaesthesia and Peripheral 
nerve block. 
2. As adjuvant for the treatment of intra operative and post operative pain.  
3. In epidural add on agent for relief of severe cancer pain.  
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4. As an anxiolytic.  
5. For sedation.  
6. To prevent or treat per operative shivering.   
Anaesthetic uses:  
1. Premedication: By acting on locus ceruleus in central nervous system 
produces sedation. Also got an anaesthesia- sparing effect. 
2. Hemodynamics: Prevents hypertension and tachycardia during 
laryngoscopy and intubation as well as during surgical stimulation.In 
cardiac and vascular sugeries it reduces the incidence of myocardial 
ischemia.                                                                          
3. Epidural:As a sole agent or in combination with opioids or local 
anaesthetics  it  provides excellent analgesia in labour analgesia. 
4. Spinal: Clonidine along with local anaesthetics improves the quality of 
analgesia and duration of block.It minimize the tourniquet pain during  
limb surgeries, and prevents shivering.  
5. Caudal:  With local anaesthetics increases the duration of caudal 
anaesthesia and analgesia by 2 or 3 times without hemodynamic side 
effects. Dose 2-3 mics/kg  
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6. Peripheral nerve blocks:  prolongs the duration of block and analgesia 
with local anaesthetics by 2 times in a dose of 75 to150 micro grams.  
7. Bier’s block:  Enhances the tolerance of tourniquet.  
8. Intra articular analgesia.  
Overdosage and treatment:  
        There is no specific antidote for clonidine overdosage. Supportive measures 
like atropine, ephedrine, i.v fluids is enough.   
For hypertensive crisis Inj.phentolamine, i.v furosemide, diazoxide can be used.  
          Yohimbine partially reverses sedation and analgesia but not  BP and heart 
rate changes produced by  epidurally injected clonidine.  
         Opioid antagonist Naloxone used as an adjunct for management of 
clonidine induced respiratory depression, hypotension and or coma. Blood 
pressure monitoring is essential after injecting naloxone because it produces 
paradoxical hypertension 
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PHARMACOLOGY OF PREGABALIN16 
Pregabalin is a structural analog of Gamma amino butyric acid and acts by 
presynaptic binding to the α-2 delta subunit of the voltage gated calcium 
channel.These channels are widely distributed in brain and the spinal cord. 
By binding to the calcium channels, pregabalin modulates the release of 
several excitatory neurotransmitters like noradrenaline, glutamate, substanceP, 
and calcitonin gene – related peptide. This leads to inhibitory modulation of 
“overexcited neurons” and returns them back to their “normal” state. 
Pregabalin reduces Tissue damage induced  hyperexcitability of dorsal 
horn neurons . 
 Pregabalin has a more appropriate pharmacological profile than 
gabapentin including dose dependent absorption and more potent than 
gabapentin at the same time producing fewer side effects 
 
Pregabalin belongs to gabapentenoid group of drugs. It possesses 
chemical structure similar to inhibitory neurotransmitter gamma amino benzoic 
acid. Pregabalin has got similar properties like the prototype drug gabapentin. 
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                                         Figure 2. Pregabalin 
 
Chemical structure of Pregabalin 
Pregabalin which is chemically S-(+)-3-isobutylgaba (Fig-1), was 
designed as a lipophilic analogue of GABA (gamma-amino butyric acid) 
substituted at the 3-position to facilitate diffusion across blood brain barrier.3-
isobutylgaba exists in isomeric forms, rendering the drug pharmacologically 
active enantiomer. 
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Drug approval 
 In Europe during july 2004 first granted the   Pfizer company approval 
for pregabalin, for the treatment of peripheral neuropathy and  partial 
seizures. 
 December 2004-The888888 Food and Drug Administration (FDA) 
approved pregabalin, for the treatment of diabetic peripheral neuropathy 
and post herpetic neuralgia.  
 The FDA approved pregabalin for use as an adjuvant in partial seizure 
treatment in june 2005. 
 March 2006- Pregabalin got approval from European commission, for 
the treatment of generalised anxiety disorder. 
Mechanism of action: 
Pregabalin has structural similarity to the inhibitory neurotransmitter 
GABA. It neither acts on GABA receptor, nor mimics it physiologically. The 
exact mechanism of action of pregabalin has not been fully known. Pregabalin 
has pharmacological profile similar to gabapentin. Pregabalin acts on the alpha 
2 delta subunit of neuronal calcium channels. 
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Pregabalin is an alpha 2 delta ligand 
 Alpha 2 delta is a subunit of presynaptic, voltage-gated calcium channel. 
The main site of action of pregabalin is alpha 2 delta subunit of neuronal 
calcium channels. Binding to this ligand reduces the depolarisation induced 
calcium entry at nerve terminals which leads to decrease in the release of 
excitatory amino acids like glutamate, noradrenaline, substance-P, and CGRP. 
This modulation ofneurotransmitter release by pregabalin is responsible for   
its anxiolytic, anticonvulsant and analgesic properties. 
There are 6 types of Voltage gated calcium channels namely P, Q, N, L, R, and 
T-type channels. N-type calcium channels are responsible for pain 
sensitization phenomenon in response to noxious stimuli. Calcium channel 
blockers binds to L-type calcium channels. L- type calcium channels are 
present in Cardiac and other peripheral tissues.  This explains the lack of 
cardiovascular side effects with pregabalin. 
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Figure  3. Structure of calcium channel  
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Dosage and administration: 
 The maximum recommended dosage for painful diabetic neuropathy is 
100 mg three times a day. The dose needs to be reduced in patients with 
reduced renal function since pregabalin eliminated via renal route. For 
peripheral neuropathy, start with low doses 75 mg per day and may be 
increased to 300 mg per day within a 7 days  based on efficacy and patient 
tolerability. 
 
PHARMACOKINETICS 
 Pregabalin has consistent dose proportional pharmacokinetics  
The mean elimination half-life of pregabalin is 6.3 hours, which is 
independent of dose and repeated administration. This consistent dose-
proportional pharmacokinetics of pregabalin provides confidence in the 
prediction of dose-response relationship in clinical practice. Administration of 
pregabalinalong with food has no effect on its absorption. 
Distribution, metabolism and elimination 
L-transporter system is responsible for transport of substances across the 
brain and gut. Pregabalin is a substrate of this L-transporter system so it crosses 
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blood brain barrier very rapidly. This property is essential for a drugs acting on 
central nervous system. 
 Pregabalin undergoes less than 2% metabolism. It is usually excreted via 
kidney in unchanged form. In renal failure patients dose reduction needed. 50% 
dose reduction needed in patients with creatinine clearance of 30 to 60 
ml/minute. 
Pregabalin versus gabapentin 
As discussed earlier pregabalin has better pharmacokinetic properties than 
gabapentin although both belongs to same group and have similar chemical 
structure. 
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Table 1.Pharmacological properties of pregabalin 
Property Clinical significance 
 
1. High affinity for α2δ receptor 
2. No effect on GABA  
3. Linear dose proportional to Cmax 
4. Lack of protein binding 
5. Negligible metabolism 
6. Renal excretion (98% unchanged) 
 
7. Rapidly cross blood brain barrier  
 
New mechanism of action 
No retinal or optic nerve toxicity 
Predictable level and dose response 
No drug interactions 
No drug interactions  
Dose reduction in renal impairment 
No hepatic effects 
Access to CNS site of action 
Cmax- maximum plasma concentration 
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Pregabalin lacks drug interactions: 
Pregabalin does not affect the liver cytochrome P450 enzyme system and 
it does not bind to plasma proteins and hence has no drug interactions. So it can 
be safely administered with other medications including anticonvulsant. 
Safety implications of pregabalin: 
Pregabalin even at high concentration does not completely block calcium 
channel function or transmitter release and hence no complication occurs in drug 
overdose. 
Clinical uses of pregabalin 
1. Adjuvant drug in partial seizures 
2. Chronic pain syndromes like diabetic peripheral neuropathy and post 
herpetic neuralgia. 
3. Chronic anxiety disorder 
4. Adjuvant in acute pain management 
 Pregabalin has anticonvulsant, sedative, analgesic and anti-hyperalgesic 
properties studies and are used for pre-operative sedation, anxiolysis, reduced 
inter-operative opioid requirement  and attenuation of hemodynamic stress 
response to laryngoscopy and tracheal intubation. 
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 Alpha 2 delta receptors are involved in the mechanism of neuronal 
hypersensitisation to noxious stimuli.Pregabalin blunts this hypersensitisation  
and helps in reducing the  post-operative pain and has got opioid sparing effect. 
Side effects and precautions: 
Pregabalin is a relatively safe drug; well-tolerated with dose-dependent adverse 
effects usually mild and transient which includes 
1. Dizziness (29%) 
2. Somnolence (22%) 
3. Dryness of mouth (9.1%) 
4. Blurred vision (6.4%) 
5. Edema (6.1%) 
6. Weight gain (5.6%) 
7.  Abnormal thoughts (5.4%) 
 Pregabalin is contraindicated in patients with history of drug allergy. FDA 
approval for pregabalin is in class C for pregnant patients.  
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REVIEW OF LITERATURE 
A number of clinical studies have been undertaken in the past to assess the 
efficacy of clonidine and pregabalin on haemodynamic changes.  
Kumkum gupta et al4  in 2011 analysed “oral premedication with 
pregabalin or clonidine for hemodynamic stability during laryngoscopy and 
laparoscopic cholecystectomy comparative evaluation  methods laparoscopic 
patients randomised to receive placebo Group I, pregabalin (150mg) Group II 
and clonidine (200microgram) Group III given 75 to 90 mins before surgery as 
oral premedication. Concluded that oral premedication with pregabalin or 
clonidine causes sedation and anxiolysis with hemodynamic stability during 
laryngoscopy and laparoscopic cholecystectomy”, without prolongation of 
recovery time and side effects. 
In Yuvesh Passi et al 5  analysed “ fifty  patients belonging to ASA status 
I or II, posted for laparoscopic Cholecystectomy were selected and randomly 
allocated to two groups A & B. Group A (clonidine) received Tab. clonidine 
150μg orally and Group B (Control) received Tab. vitamin B complex orally as 
premedication 60-90 minutes before laparoscopy. Heart rate and mean blood 
pressure were recorded prior to intubation, 15 min after  intubation, at skin 
incision, 15 min and 30 min after  pneumoperitoneum  and 15 min after  
pneumoperitoneum release. Concluded that premedication with oral  tablet 
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clonidine 150 μg provides stable hemodynamics in laparoscopic 
cholecystectomy” patients. 
Malek et al6 in 1999 analysed in their work involving 21 patients the 
incidence of these effects and tried to suppress them by premedication with 
clonidine. 21 patients were given 0.15 mg clonidine in an infusion 15 minutes 
before operation and 21patients were given 0.15 mg clonidine by the i.m. route 
60-90 mins before operation. A highly significant drop in the incidenceof 
hypertension was recorded during operation for systolic pressure (p < 0.001) 
after both ways of administration, as well as of diastolic pressure (p < 0.01 for 
intravenous and p < 0.05 for intramuscular premedication). Premedication with 
intravenous clonidine can be recommended as a routine procedure before 
laparoscopic cholecystectomies. 
Yu  et al7  in 2003 analysed “ thirty-two patients scheduled for elective 
laparoscopic cholecystectomy were recruited for a prospective, randomized, 
double-blinded comparative study. They were allotted randomly to two groups: 
Placebo and clonidine. Patients in the placebo group (n = 16) were premedicated 
with oral antacid, while those in the clonidine group (n = 16) were premedicated 
with oral clonidine 150 µg before anesthesia. Analysis of heart rate variability 
was used to quantify the control of heart rate at baseline, and during the 
pneumoperitoneum and recovery periods. Time of the first request for 
postoperative analgesic and cumulative analgesic requirements in 24 h were 
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recorded. Concluded that Clonidine preserves heart rate control in 
pneumoperitoneum and recovery periods”. Oral clonidine premedication  
reduces the postoperative analgesia requirement.  
Mrinmoy et al8  in 2007 analysed  “sixty patients of ASA I & II, posted  
for elective laparoscopic cholecystectomy were recruited for a prospective 
randomized, double-blinded comparative study. They were randomly allocated  
into  two groups to receive either oral clonidine 150 µg (Group C) or ranitidine 
150 mg (Group P) 90 minutes before surgery. Significant increase in heart rate 
was noted after pneumoperitoneum in Group P as compared to Group C. 
Similarly, rise in systolic arterial pressure, diastolic arterial pressure and mean 
arterial pressure was more in Group P following pneumoperitoneum. Incidence 
of  PONV and shivering was also less in Group C. Concluded that clonidine 
premedication provides better  haemodynamic stability”, so it can be 
recommended as a routine premedication for laparoscopic procedures. 
In Masayoshi uchida et al9 studied in 2004,  sixty  patients of ASA I were 
randomly allocated into two groups. Thirty patients received tab. famotidine 20 
mg (control group) orally 90 min before the induction, the remaining 30 patients 
received clonidine 5 μg/kg and famotidine 20 mg (clonidine group).  MAP, CI 
and HR responses to hypercapnia in the clonidinel group were significantly 
attenuated compared with control group. Plasma norepinephrine concentrations  
were significantly lower in clonidine group.  
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In Laisalmi et al10  study in 2001; The “effects of clonidine 4.5 mg/kg or 
saline on hemodynamics,  neuroendocrine response and renal parameters were 
compared in 30 healthy patients undergoing laparoscopic cholecystectomy.Heart 
rate, arterial blood pressures and plasma renin activity were lower during and 
after pneumoperitoneum in patients with clonidine. There were no differences in 
urine output, urine oxygen tension (reflecting medullary perfusion), or 
antidiuretic hormone between the groups. N-acetyl-b-D-glucosaminidase, a 
marker of proximal tubular damage, was minimally elevated after clonidine. 
Concluded that clonidine enabled stable hemodynamics” and prevented 
activation of RAAS seen as unchanged plasma renin activity.  
In Sung et al11 study; “One hundred and ten patients scheduled for elective 
laparoscopic cholecystectomy  were randomly allotted to either of the placebo or 
clonidine group. Patients of the placebo group (n = 65) were premedicated with 
oral antacid (300 mg), while those in the clonidine group (n = 45) were 
premedicated with oral clonidine 150 micrograms prior to anesthesia. The 
premedication was given 60 to 90 min before the anticipated time of induction of 
anesthesia. Concluded that oral clonidine premedication helped to provide 
perioperative hemodynamic stability, spared the use of isoflurane and reduced 
the requirement of postoperative analgesia so as to smoother the way to recovery 
in patients undergoing laparoscopic cholecystectomy”. 
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Jokela R et al12 conducted a “randomized control trial of perioperative 
administration of pregabalin for pain after laparascopic hysterectomy. In this 
study they evaluated the control of pain after perioperative administration of 
pregabalin 300 or 600 mg. 91 patients scheduled for laparascopic hysterectomy 
were randomized to receive either diazepam 10mg, pregabalin 150mg or 
pregabalin 600 mg as premedication and the dose was repeated after  12 hours 
except the diazepam group where they received placebo. Until the first 
postoperative morning analgesia was provided by oxycodone using patient 
controlled analgesia. This study concluded that perioperative administration of 
pregabalin 600mg decreases oxycodone consumption compared with diazepam 
10mg” but is associated with an increased incidence of side effects. 
Dinesh k et al13 in march 2015 analysis done on comparative study of oral 
pregabalin 150 mg and clonidine 200 microgram  for attenuation of 
haemodynamic responses to laryngoscopy and tracheal intubation. Concluded 
that both pregabalin and clonidine successfully attenuated the hemodynamic 
response to laryngoscopy and tracheal intubation. Pregabalin better attenuates 
pressor response and clonidine better attenuates tachycardia response. 
Balaban F et al14 analysed the efficacy of two different doses of 
preoperative pregabalin (150 mg and 300 mg) on pain relief and total opiod 
consumption after laparascopic cholecystectomy. The results of this study 
showed that preemptive pregabalin decreased pain scores and postoperative 
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fentanyl requirement in patients undergoing laparascopic cholecystectomy in a 
dose dependent manner. There was also no difference in side effects between 
two different groups on two different dosages. 
George RB et al15 performed a study to determine if low dose of 
pregabalin could decrease opioid use following abdominal hysterectomy while 
comparing placebo.   Patients were randomised into three groups- pregabalin 75 
mg(P75), pregabalin 150 mg(P150) and placebo. The study drug was 
administered two hours prior to surgery and 12 hour following the initial dose. 
Postoperative pain was managed using patient controlled analgesia with 
morphine. Pain at rest and movement as well as nausea were assessed. Mean 
cumulative morphine consumptionwas noted postoperatively. This clinical trial 
showed pregabalin treatment may not be use in reducing opioid use upto 24 hour 
postoperatively. 
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METHODOLOGY 
SOURCES OF DATA  
Data was collected from 90 ASA I and II patients scheduled for 
laparoscopic surgeries aged between 18 – 60 years at Tirunelveli  Medical 
College and Hospital,Tirunelveli. Both study groups and control were selected 
from these patients. The study was conducted over a period of four months. 
INCLUSION CRITERIA : 
 ASA I and  II patients 
 Both gender 
 Age 18 -60yrs  
EXCLUSION CRITERIA  
• Pre-existing cardiac disease 
• Known case of  Systemic Hypertension 
• Renal ysfunction  
• Hepatic dysfunction 
• Anticipated difficult intubation 
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• Patient refusal 
• Allergic to any of the study drugs 
METHODS  
The study was a prospective, randomized placebo control study. 
Computer based randomization was done. 
 MATERIALS  
Clonidine tablet  200µg 
Pregabalin tablet 150mg 
Placebo tablets 
Drugs- Injection Midazolam, Injection Glycopyrrolate, Inj Fentanyl,  
Inj.propofol, Inj. Vecuronium, Inj. Neostigmine, Isoflurane, emergency drugs, 
Normal Saline and Ringer Lactate. 
Monitors- ECG, NIBP, SPO2, EtCo2. 
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Study design: 
The patients satisfying inclusion criteria were randomly allocated into 
three groups each containing 30 patients. 
Preanaesthetic evaluation:  
1. History  
2. Clinical examination  
3. Relevant investigations  
4. Informed consent from patients  
Preanaesthetic medication was given with tab.ranitidine 150 mg and 
tab.diazepam 10 mg the night before surgery. Patients were randomly allocated 
into three groups. 
1) Group I– Those who receive placebo tablets. 
2) Group II - Those who receive Clonidine tablets ( 200 µg)  
3) Group III - Those who receive Pregabalin tablets (150 mg)
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The tablets given orally with sips of water 60 mins before induction of 
general anesthesia. Before administration of oral premedication , each patients 
baseline heart rate, systemic blood pressure, diastolic blood pressure and mean 
arterial pressure and SpO2  recorded. 
 After shifting the patient to the operation table SpO2, NIBP, ECG 
monitors were attached. The baseline values were recorded. IV access was 
established. Inj.midazolam 0.03mg/kg and inj.glycopyrrolate 0.2 mg i.v. given 
and patient pre-oxygenated for 3 minutes. Anesthesia was induced with 
inj.propofol 2mg/kg, inj.fentanyl  2 microgram/kg and inj.vecuronium 0.1 
mg/kg. Proper size cuffed PVC endotracheal tube was inserted orotracheally. 
Anaesthesia was maintained with NitrousOxide 67%, Oxygen 33% ,isoflurane 
1% and intermittent doses of inj.vecuronium  and inj.fentanyl. Ventilation was 
controlled mechanically and was adjusted to keep ETCO2 between 30 to 35 mm 
of Hg. The intra abdominal CO2 pressure was kept between 12 -14 mm of Hg. A 
ryles tube was inserted and suction applied to empty the contents of stomach 
after intubation and also before extubation.  
 Haemodynamic instability  was defined as  “Heart rate and blood pressure fall 
or rise more than 15% from baseline” and was treated accordingly. Systemic 
arterial pressure including the systolic, diastolic and mean arterial pressure, heart 
rate, SpO2 were recorded as   
(1) Pre operative (pre op) 
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(2) One minute after endotracheal intubation (AI 1 MIN) 
(3) Five minutes after endotracheal intubation (AI 5 MIN) 
(4) One minute after pneumoperitoneum  (AP 1 MIN) 
(5) Five minutes after pneumoperitoneum  (AP 5 MIN) 
(6) Fifteen minutes after pneumoperitoneum  (AP 15 MIN) 
(7) Thirty minutes after pneumoperitoneum  (AP 30 MIN) 
(8) Fourtyfive minutes after pneumoperitoneum (AP 45 MIN) 
(9) After pneumoperitoneum release   ( PR ) 
(10) After extubation ( AE ) 
Reversal of muscle relaxation was done with inj.glycopyrolate 0.01 mg/kg 
body weight and inj.neostigmine 0.05 mg /kg and patient was extubated.   
Postoperatively all episodes of PONV and drowsiness experienced by the 
patient during the first 6 hours after anaesthesia  was recorded. Rescue 
Antiemetic (inj.ondansetron 4mg ) was used if patient had nausea or vomiting 
and the number of doses required was monitored. Post operative pain and 
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sedation of the patient was monitored for 6 hours using the visualanalog scale 
and the ramsay sedation score respectively.  
Pain quantification was done on a modified Visual Analog Scale Score 
between 0 and 10 (0 = no pain to 10 = worst imaginable pain. 
 
Figure 4.Visual Analog Scale Scoring 
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RAMSAY SEDATION SCORE 
LEVELS 1 -3 patient awake  
      Level  1-anxious and agitated or restless or both  
Level  2-cooperative and oriented   
      Level  3-responds to commands only  
LEVEL 4-6 patient asleep, responds to light glabellar tap or     loud auditory 
stimulus   
  Level   4 –Brisk response  
      Level   5 – Sluggish response  
      Level   6 –No response  
The pain scores, sedation scores were recorded preoperatively, after extubation 
then at 1, 2, 4 and 6 hours. 
Statistical Methods  
Information collected regarding all the selected cases were recorded in a Master 
Chart. The statistical analysis was done using SPSS statistics software version. 
       A 'p' value less than 0.05 is taken to denote significant relationship.  
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RESULTS 
DEMOGRAPHIC PROFILES 
The three groups were comparable in  characteristics like age, sex, ASA and 
baseline parameters. 
Table 2.Relationship between the demographic variables and other variables. 
 
Demographic 
profile 
Group1 
(Mean±SD) 
 
Group 2 
(Mean±SD) 
 
 
Group3 
(Mean± SD) 
P value 
AGE 
44.763±6.972 44.1±8.623 45.6±7.892 
0.11 
SEX 
14:24 12:18 12:18 
0.545 
ASA 
22:16 16:14 15:15 
0.778 
HR 
77.815±5.765 82.2±4.759 78.3±6.539 
0.511 
SBP 
124.81±10.88 121.266±9.860 121.7±9.804 
0.222 
DBP 
77.394±7.027 75.933±8.901 78±7.1798 
0.06 
MAP 
92.947±7.738 90.3±8.0693 92.2±7.344 
0.088 
DURATION 
54.166±5.736 53.333±6.0647 53.2±5.865 
0.81 
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Inference 
Since the p value is  greater than 0.05, there is no significant relationship 
between the group 1,2 and 3 in terms of age,sex, ASA, duration, Baseline HR, 
SBP, DBP 
and MAP. 
Figure 5.Relationship between the demographic variables and other variables. 
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Figure 6.Relationship between the gender distribution. 
 
Figure 7.Comparison of ASA status 
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Figure 8. Comparisonbetween baseline parameters.
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Table 3.comparingHR, SBP, DBP, MAP in group 1,2 and 3 
GROUP 1 (Mean±SD) 2 (Mean±SD) 3 (Mean±SD) p-value 
HR preop 81.39±5.091 77.13±5.734 79.9±5.845 0.008 
HR AI 1min 91.08±8.423 79.63±5.786 84.83±6.502 0 
HR AI 5min 88.6±4.868 77.67±6.11 82.23±5.557 0.08 
HR AP 1min 99.26±9.83 82.4±6.134 91.37±7.937 0 
HR AP 5min 93.79±11.989 80.53±6.852 92.37±7.591 0 
HR AP 15min 95.57±9.676 80.93±6.512 93.9±7.053 0 
HR AP 30min 92.95±7.763 78.13±6.986 86.5±7.243 0 
HR AP 45min 89.05±5.337 77.1±7.029 87.4±7.025 0 
HR PR 84.95±4.893 74.3±6.587 83.8±3.978 0.772 
HR AE 77.39±36.403 79.33±4.656 74.43±30.978 0.005 
SBP preop 123.68±9.779 118.47±9.475 119.83±9.158 0.006 
SBP AI 1min 148.97±16.747 116.87±11.443 124.87±12.719 0 
SBP AI 5min 130.73±9.27 114.83±10.596 118.03±10.833 0.81 
SBP AP 1min 147.34±13.921 124.3±9.444 121.3±14.089 0 
SBP AP 5min 142.74±16.003 123.4±8.439 128.93±14.225 0 
SBP AP 15min 146.97±10.545 123.9±7.522 128.9±13.33 0 
SBP AP 30min 134.37±16.534 124.2±8.556 128.07±14.701 0.012 
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SBP AP 45min 130.61±13.962 122.67±8.727 125.27±14.946 0.039 
SBP PR  111.92±1.075 101.1±15.302 111.8±1.375 0.661 
SBP AE 116.21±1.473 111.37±0.964 115.1±1.296 0 
DBP preop 77.82±6.939 76.8±9.155 76.97±6.636 0.024 
DBP AI 1min 96.5±11.217 76.33±8.899 88.27±9.681 0 
DBP AI 5min 86.37±6.066 74.93±8.606 81.33±15.94 0.054 
DBP AP 1min 98.32±11.211 77.37±8.406 92.97±10.656 0 
DBP AP 5min 94.73±11.216 79.03±7.636 94.37±10.761 0 
DBP AP 
15min 99.67±8.393 79.6±7.309 95.27±10.471 0 
DBP AP 
30min 94.18±11.118 77.4±8.904 91.03±12.016 0 
DBP AP 
45min 92.58±9.61 76.77±7.994 87.87±11.655 0 
DBP PR 83.21±8.048 73.97±8.791 74.57±29.726 0.083 
DBP AE 74.79±40.052 61.93±8.432 67.7±35.967 0 
MAP preop 93.27±6.887 90.7±8.412 93.03±6.843 0 
MAP AI 1min 113.97±12.253 89.83±8.595 100.47±9.343 0 
MAP AI 5min 93.84±42.138 88.27±8.094 91.5±12.292 0.112 
MAP AP 1min 114.68±11.407 92.03±7.573 104.4±10.536 0 
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MAP AP 5min 110.47±12.096 93.8±6.682 106.13±9.864 0 
MAP AP 
15min 111.08±48.14 94.33±6.222 106.47±9.698 0.002 
MAP AP 
30min 105.5±11.825 93±7.529 105.4±10.978 0 
MAP AP 
45min 103.87±10.246 92.1±6.984 101.73±11.064 0 
MAP PR 61.92±40.494 48.93±24.125 51.87±42.282 0.094 
MAP AE 95.42±18.797 82.27±20.671 87.93±39.471 0 
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Inference 
a) Since the p value of heart rate pre op, AI 1 min, AP 1 min, AP 5 min, AP 
15 min, AP 30 min, AP 45 min, and   AE are lesser than 0.05, there is 
significant relationship between the group 1,2 and 3 and the variable. 
Based on the mean table, it can be concluded that the heart rate of group 
one is greater than group 3 and group 3 is greater than group 2. 
 
b) Since the p value of heart rate AI 5 min and Heart rate PR greater than 
0.05, there is no significant relationship between the group 1,2 and 3 and 
the variables. 
 
 
c) Since the p value of Systolic blood pressure pre op, SBP AI 1 min, SBP 
AP 1 min, SBP AP 5 min, SBP AP 15 min, SBP AP 30 min, SBP AP 45 
min and SBP AE are lesser than 0.05, there is significant relationship 
between the group 1,2 and 3 and the variable. Based on the mean table, it 
can be concluded that the Systolic blood pressure of group 1 is greater 
than group 3 and group 3 is greater than group 2. 
 
d) Since the p value of systolic blood pressure AI 5 min and SBP PR greater 
than 0.05, there is no significant relationship between the group 1,2 and 3 
and the variables 
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e) Since the p value of Diastolic blood pressure pre op, DBP AI 1 min, DBP 
AP 1 min, DBP AP 5 min, DBP AP 15 min, DBP AP 30 min, DBP AP 45 
min and DBP AE are lesser than 0.05, there is significant relationship 
between the group 1,2 and 3 and the variable. Based on the mean table, it 
can be concluded that the Diastolic blood pressure of group one is greater 
than group 3 and group 3 is greater than group 2. 
 
f) Since the p value of diastolic blood pressure AI 5 min and DBP PR 
greater than 0.05, there is no significant relationship between the group 
1,2 and 3 and the variables 
 
 
g) Since the p value of MAP pre op, MAP AI 1 min, MAP AP 1 min, MAP 
AP 5 min, MAP AP 15 min, MAP AP 30 min, MAP AP 45 min and MAP 
AE are lesser than 0.05, there is significant relationship between the group 
1,2 and 3 and the variable. Based on the mean table, it can be concluded 
that the MAP of group 1 is greater than group 3 and group 3 is greater 
than group 2. 
 
h) Since the p value of MAP AI 5 min and MAP PR greater than 0.05, there 
is no significant relationship between the group 1,2 and 3 and the 
variables 
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Figure 9. Comparing Heart rate in group1,2 & 3. 
 
 
 
 
Figure 10. Comparing SBP in group1,2 & 3. 
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Figure 11. Comparing DBP in group1,2 & 3. 
 
 
 
 
Figure 12. Comparing MAP in group1,2 & 3. 
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Figure 13. Comparing HR in group1,2 & 3 
 
 
 
 
Figure 14. Comparing SBP in group1,2 & 3 
 
 
 
 
0
20
40
60
80
100
120
Group 1
Group 2
Group 3
0
20
40
60
80
100
120
140
160
Group 1
Group 2
Group 3
56 
 
Figure 15. Comparing DBP in group1,2 & 3 
 
 
 
 
Figure 16. Comparing MAP in group1,2 & 3 
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Table 4.Comparison of HR, SBP, DBP and MAP with group 1 and 2 
 
       GROUP  1 (Mean±SD) 2 (Mean±SD) p value 
HR preop  81.39±5.091 77.13±5.734 0.032 
HR AI 1min  91.08±8.423 79.63±5.786 0 
HR AI 5min  88.6±4.868 77.67±6.11 0.07 
HR AP 1min  99.26±9.83 82.4±6.134 0 
HR AP 5min  93.79±11.989 80.53±6.852 0 
HR AP 15min  95.57±9.676 80.93±6.512 0 
HR AP 30min  92.95±7.763 78.13±6.986 0 
HR AP 45min  89.05±5.337 77.1±7.029 0 
HR PR  84.95±4.893 74.3±6.587 0.434 
HR AE  77.39±36.403 79.33±4.656 0 
SBP preop  123.68±9.779 118.47±9.475 0.03 
SBP AI 1min  148.97±16.747 116.87±11.443 0 
SBP AI 5min  130.73±9.27 114.83±10.596 0.99 
SBP AP 1min  147.34±13.921 124.3±9.444 0 
SBP AP 5min  142.74±16.003 123.4±8.439 0 
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SBP AP 15min  146.97±10.545 123.9±7.522 0 
SBP AP 30min  134.37±16.534 124.2±8.556 0.003 
SBP AP 45min  130.61±13.962 122.67±8.727 0.008 
SBP PR   11.92±1.075 10.1±15.302 0.384 
SBP AE  14.21±1.473 11.37±0.964 0 
DBP preop  77.82±6.939 76.8±9.155 0.004 
DBP AI 1min  96.5±11.217 76.33±8.899 0 
DBP AI 5min  86.37±6.066 74.93±8.606 0.51 
DBP AP 1min  98.32±11.211 77.37±8.406 0 
DBP AP 5min  94.73±11.216 79.03±7.636 0 
DBP AP 15min  99.67±8.393 79.6±7.309 0 
DBP AP 30min  94.18±11.118 77.4±8.904 0 
DBP AP 45min  92.58±9.61 76.77±7.994 0 
DBP PR  83.21±8.048 73.97±8.791 0.09 
DBP AE  74.79±40.052 61.93±8.432 0.022 
MAP preop  93.27±6.887 90.7±8.412 0.004 
MAP AI 1min  113.97±12.253 89.83±8.595 0 
MAP AI 5min  93.84±42.138 88.27±8.094 0.285 
MAP AP 1min  114.68±11.407 92.03±7.573 0 
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MAP AP 5min  110.47±12.096 93.8±6.682 0 
MAP AP 15min  111.08±48.14 94.33±6.222 0.015 
MAP AP 30min  105.5±11.825 93±7.529 0 
MAP AP 45min  103.87±10.246 92.1±6.984 0 
MAP PR  61.92±40.494 48.93±24.125 0.066 
MAP AE  95.42±18.797 82.27±20.671 0 
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Inference 
a) Since the p value of heart rate pre op, AL 1 min, AP 1 min, AP 5 min, AP 
15 min, AP 30 min, AP 45 min and HR AE are lesser than 0.05, there is 
significant relationship between the group 1and 2 and the variable. Based 
on the mean table, it can be concluded that the heart rate of group one is 
greater than group 2. 
 
b) Since the p value of heart rate AL 5 min and Heart rate PR greater than 
0.05, there is no significant relationship between the group 1 and 2 and the 
variables. 
 
 
c) Since the p value of SBP pre op, AL 1 min, AP 1 min, AP 5 min, AP 15 
min, AP 30 min, AP 45 min and SBP AE are lesser than 0.05, there is 
significant relationship between the group 1 and 2 and the variable. Based 
on the mean table, it can be concluded that the heart rate of group one is 
greater than group 2. 
 
d) Since the p value of SBP AL 5 min and SBP PR greater than 0.05, there is 
no significant relationship between the group 1 and 2 and the variables. 
 
 
61 
 
e) Since the p value of DBP pre op, AL 1 min, AP 1 min, AP 5 min, AP 15 
min, AP 30 min, AP 45 min and DBP AE are lesser than 0.05, there is 
significant relationship between the group 1 and 2 and the variable. Based 
on the mean table, it can be concluded that the heart rate of group one is 
greater than group 2. 
 
f) Since the p value of DBP AL 5 min and DBP PR greater than 0.05, there 
is no significant relationship between the group 1 and 2 and the variables. 
 
 
g) Since the p value of MAP pre op, AL 1 min, AP 1 min, AP 5 min, AP 15 
min, AP 30 min, AP 45 min and MAP AE are lesser than 0.05, there is 
significant relationship between the group 1 and 2  and the variable. Based 
on the mean table, it can be concluded that the heart rate of group one is 
greater than group 2.. 
 
h) Since the p value of MAP AL 5 min and MAP PR greater than 0.05, there 
is no significant relationship between the group 1 and 2, and the variables. 
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Table 5.Comparison of HR, SBP, DBP, MAP with group 1 and 3 
GROUP 1 (Mean±SD) 3 (Mean±SD)  P value 
HR preop 81.39±5.091 79.9±5.845 0.004 
HR AI 1min 91.08±8.423 84.83±6.502 0.001 
HR AI 5min 88.6±4.868 82.23±5.557 0.07 
HR AP 1min 99.26±9.83 91.37±7.937 0.001 
HR AP 5min 93.79±11.989 92.37±7.591 0.019 
HR AP 15min 95.57±9.676 93.9±7.053 0.009 
HR AP 30min 92.95±7.763 86.5±7.243 0.016 
HR AP 45min 89.05±5.337 87.4±7.025 0.002 
HR PR 84.95±4.893 83.8±3.978 0.442 
HR AE 77.39±36.403 74.43±30.978 0.017 
SBP preop 123.68±9.779 119.83±9.158 0.002 
SBP AI 1min 148.97±16.747 124.87±12.719 0 
SBP AI 5min 130.73±9.27 118.03±10.833 0.27 
SBP AP 1min 147.34±13.921 121.3±14.089 0 
SBP AP 5min 142.74±16.003 128.93±14.225 0 
SBP AP 15min 146.97±10.545 128.9±13.33 0 
SBP AP 30min 134.37±16.534 128.07±14.701 0.006 
SBP AP 45min 130.61±13.962 125.27±14.946 0.034 
SBP PR 111.92±1.075 111.8±1.375 0.685 
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SBP AE 116.21±1.473 115.1±1.296 0 
DBP preop 77.82±6.939 76.97±6.636 0 
DBP AI 1min 96.5±11.217 88.27±9.681 0.002 
DBP AI 5min 86.37±6.066 81.33±15.94 0.111 
DBP AP 1min 98.32±11.211 92.97±10.656 0.05 
DBP AP 5min 94.73±11.216 94.37±10.761 0.003 
DBP AP 15min 99.67±8.393 95.27±10.471 0.008 
DBP AP 30min 94.18±11.118 91.03±12.016 0.005 
DBP AP 45min 92.58±9.61 87.87±11.655 0.044 
DBP PR 83.21±8.048 74.57±29.726 0.06 
DBP AE 74.79±40.052 67.7±35.967 0.05 
MAP preop 93.27±6.887 93.03±6.843 0.001 
MAP AI 1min 113.97±12.253 100.47±9.343 0 
MAP AI 5min 93.84±42.138 91.5±12.292 0.091 
MAP AP 1min 114.68±11.407 104.4±10.536 0 
MAP AP 5min 110.47±12.096 106.13±9.864 0.006 
MAP AP 15min 111.08±48.14 106.47±9.698 0 
MAP AP 30min 105.5±11.825 105.4±10.978 0.002 
MAP AP 45min 103.87±10.246 101.73±11.064 0.004 
MAP PR 61.92±40.494 51.87±42.282 0.322 
MAP AE 95.42±18.797 87.93±39.471 0.003 
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Inference 
a) Since the p value of heart rate pre op, AL 1 min, AP 1 min, AP 5 min, AP 
15 min, AP 30 min, AP 45 min and HR AE are lesser than 0.05, there is 
significant relationship between the group 1and 2 and the variable. Based 
on the mean table, it can be concluded that the heart rate of group one is 
greater than group 3. 
 
b) Since the p value of heart rate AL 5 min and Heart rate PR greater than 
0.05, there is no significant relationship between the group 1 and 3 and the 
variables. 
 
 
c) Since the p value of SBP pre op, AL 1 min, AP 1 min, AP 5 min, AP 15 
min, AP 30 min, AP 45 min and SBP AE are lesser than 0.05, there is 
significant relationship between the group 1 and 3 and the variable. Based 
on the mean table, it can be concluded that the heart rate of group one is 
greater than group 3. 
 
d) Since the p value of SBP AI 5 min and SBP PR greater than 0.05, there is 
no significant relationship between the group 1 and 3 and the variables. 
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e) Since the p value of DBP pre op, AI 1 min, AP 1 min, AP 5 min, AP 15 
min, AP 30 min, AP 45 min and DBP AE are lesser than 0.05, there is 
significant relationship between the group 1 and 3 and the variable. Based 
on the mean table, it can be concluded that the heart rate of group one is 
greater than group 3. 
 
f) Since the p value of DBP AL 5 min and DBP PR greater than 0.05, there 
is no significant relationship between the group 1 and 3 and the variables. 
 
 
g) Since the p value of MAP pre op, AL 1 min, AP 1 min, AP 5 min, AP 15 
min, AP 30 min, AP 45 min and MAP AE are lesser than 0.05, there is 
significant relationship between the group 1 and 3 and the variable. Based 
on the mean table, it can be concluded that the heart rate of group one is 
greater than group 3. 
 
h) Since the p value of MAP AI 5 min and MAP PR greater than 0.05, there 
is no significant relationship between the group 1 and 3, and the variables. 
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Table 6.Vas score comparison 
 
 
 
  
VAS Group 
1(Mean±SD) 
Group 2 
(Mean±SD) 
Group 3 
(Mean±SD) 
P value 
Pre-op 1.5±0.507 0.87±0.575 1.0±0.458 0.00 
AE 5.13±0.704 3.26±0.826 4.37±0.527 0.05 
1 hr 5.58±0.599 4.25±0.528 5.01±0.957 0.002 
2 hr 6.34±0.627 4.95±0.113 5.88±0.492 0.015 
4 hr 5.82±0.563 4.88±0.368 5.07±0.492 0.03 
6 hr 5.79±0.528 2.87±0.673 3.28±0.992 0.00 
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Figure 17. Comparing VAS Score in group1,2 & 3 
 
 
 
Inference 
There is a significant relationship between the VAS score of group 1, 2 and 3. 
Based on the mean, the VAS score of group 2 is less than group 3 which is less 
than group 1. 
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Table 7.Sedation score 
 Group 1 
(Mean±SD) 
Group 2 
(Mean±SD) 
Group 3 
(Mean±SD) 
P value 
Pre op 1±0.21 2.33±0.479 1.77±0.626 0.000 
AE 1.45±0.686 2.57±0.504 2.13±0.571 0.028 
1 hr 1.66±0.669 3.57±0.504 2.17±0.592 0.001 
2 hr 1.61±0.495 2.87±0.434 2.23±0.679 0.006 
4 hr 1.71±0.46 3±0.371 1.9±0.803 0.000 
6 hr 1.74±0.446 2.83±0.531 1.77±0.898 0.002 
 
Figure 18. Comparing Sedation score in group1,2 & 3 
 
 
1.00
1.45
1.66 1.61 1.71
1.74
2.33
2.57
3.57
2.87
3.00
2.83
1.77
2.13 2.17 2.23
1.90
1.77
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
Sedationpreop sedationae sedation1 sedation2 sedation4 sedation6
Series1
Series2
Series3
69 
 
 
 
Inference 
There is a significant association between the sedation score of group 1, 2 and 3. 
The sedation score of group 2 is greater than group 3 which is in turn greater 
than group 1. 
 
Table 8.Fentanyl requirement 
Group 1 (Mean±SD) 2 (Mean±SD) 3 (Mean±SD) p-value 
Mean 153.95±27.365 29.33±15.071 59.33±21.645 0.004 
 
Figure 19. Comparing Fentanyl requirement in group1,2 & 3 
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Inference 
There is a significant difference between the Fentanyl requirement in 
group 1, 2 and 3. Group 1 requires more than group 3 and group 3 requires more 
than group 2. 
 
Table 9.Side effects 
Group Nausea Vomitting Drowsiness 
1 2 (2.1%) 3 (3.1%) 3 (3.1%) 
2 1 (1.1%) 2 (2.1%) 13 (13.3%) 
3 2 (2.1%) 3 (3.1%) 5 (5.1%) 
 
Inference 
Drowsiness is more common in group 2 than other groups. Other side effects 
were having insignificant difference  among the groups. 
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DISCUSSION 
During laparoscopy pneumoperitoneum produces significant 
haemodynamic changes, which are well tolerated in normal healthy patients but 
in patients with compromised cardiorespiratory function are detrimental. Various 
pharmacological drugs have been used to counteract these hemodynamic effects 
of pneumoperitoneum. This study was carried out in 90 adult patients, to 
evaluate the effect of oral clonidine 200 µg and pregabalin 150 mg in attenuating 
haemodynamic stress response associated with pneumoperitoneum. 
Clonidine, is a selective α2 adrenergic agonist and an imidazoline 
derivative . It is an antihypertensive drug. It produces a fall in the heart rate and 
blood pressure associated with decreased SVR and cardiac output. Clonidine 
inhibits the vasopressin and catecholamine release and there by modulates the 
haemodynamic changes produced by pneumoperitoneum.  
Joris et al17 used very high dose of clonidine (8 µg/kg) for reducing  
catecholamine and vasopressin levels  following pneumoperitoneum. Aho et al 
used 3 µg/kg and 4.5 µg/kg clonidine for suppression of haemodynamic response 
to pneumoperitoneum.  Malek et al6 used 150 µg of clonidine as i.v. infusion and 
intramuscularly while Sung et al11 and Yu et al 7used 150 µg of oral clonidine as 
premedication for maintenance of haemodynamic stability during 
pneumoperitoneum.  
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In my study  200µg of oral Clonidine was used given 60 minutes before 
induction, there was no significant rise in the heart rate throughout the intra 
operative period.  
Kumkum gupta et al4  in 2011 analysed oral premedication with 
pregabalin (150mg) Group II or clonidine (200microgram) Group III given 75 to 
90 mins before surgery as oral premedication. 
In my study I used the same dosage of pregabalin and clonidine given 
orally 60 mins before surgery. 
In my study the placebo group had hemodynamic instability in the form of 
rise in heart rate, systolic BP, diastolic BP and mean arterial pressure, but  in 
clonidine and pregabalin group there is no rise in BP throughout the surgery 
maintaining the haemodynamic stability. The difference is statistically 
significant. Clonidine has a better stability than the pregabalin group. 
Clonidine interacts with the endogenous opiates beta-endorphins. The 
plasma level of beta-endorphins increases significantly after laproscopy. The 
blunting effect of clonidine on hemodynamics and plasma beta-endorphins may 
reflect a deeper level of anaesthesia in those receiving Clonidine.  
Marimony et al8 (2007) found “a decreased incidence of nausea and 
vomiting in patients receiving Clonidine. Clonidine increases gastrointestinal 
motility by decreasing sympathetic outflow and increasing parasympathetic 
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outflow from the central nervous system”. Though many workers have reported 
the antiemetic property of clonidine, the mechanism by which it acts needs 
further investigation.  
There was a reduction in the PONV in patients receiving Clonidine , as 
compared to control  and pregabalin. But this reduction is not statistically 
significant. 
Sung et al11 (2000) and Yu et al7 (2003) found that preoperative clonidine 
admistration reduced the post operative analgesic requirement. In my study also 
there was a significant reduction in the post operative analgesic requirement in 
patients receiving clonidine. Pregabalin group also  had reduced post operative 
analgesic requirement but the reduction in pregabalin group is less than the 
clonidine group. 
In my study the post operative sedation score was observed for 6 hrs 
postoperatively and was found that clonidine group had a significantly high 
sedation score than other groups. 
It was observed that post operative anti emetic requirement was 
insignificant in all the groups.  
There is a significant difference between the Fentanyl requirement in group 1, 2 
and 3. Group 1 requires more than group 3 and group 3 requires more than group 
2. 
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Post operative analgesic requirement was also observed to be significantly 
lower in Clonidine groupand pregabalin group as compared to the placebo group. 
It was found to be more decreased in clonidine group than with pregabalin group. 
There is a significant association between the sedation score of group 1, 2 
and 3. The sedation score of clonidine group  is greater than pregabalin  group  
which is in turn greater than placebo group . 
No adverse effect was observed with the study group during the intra 
operative and post operative period.  
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SUMMARY 
Haemodynamicchanges during laparoscopic surgery is attributed to the 
stress response to pneumoperitonium.  
We studied ninety patients of both sexes coming toTirunelveli edical 
College hospital for elective laparoscopic surgeries. The patients were 
randomized in to three groups to receive placebo tablet in group I, 200 
microgram of clonidine in Group II and 150 mg of pregabalin in group III about 
60 mins before induction of anaesthesia.Patients were observed for intra 
operative heart rate, systolic BP, diastolic BP and mean BP. Hemodynamic 
instability was defined as heart rate and blood pressure fall or rise not more than 
15% from base line. 
 Both Clonidine and pregabalin were effective in producing intra 
operative hemodynamic stability as compared to the control group by blunting 
the stress response to pneumoperitonium but the hemodynamic stability is better 
with clonidine group than  pregabalin group, which itself is better than placebo 
group. 
 The pain scores was significantly reduced in clonidine and pregabalin 
groups when compared to the placebo group but the reduction in scores in the 
pregabalin group is significantly less than thatof the clonidine group.  
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The sedation score is higher in clonidine group when compared to placebo and 
pregabalin. 
Intraoperative fentanyl requirement is more with placebo group than pregabaline 
group , which itself  higher than clonidine group. 
Drowsiness is more with clonidine group than pregabalin and placebo. 
Post operative nausea and vomiting incidence was similar in all groups. 
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CONCLUSION 
This study showed that an oralpremedication dose of clonidine of 200 
µgor oral dose of pregabalin 150 mg attenuated the hemodynamic stress response 
produced by laryngoscopy and pneumoperitonium in patients undergoing 
laparoscopic surgeries. It showed that oral clonidine 200 µgproduced better 
hemodynamic stability than oralpregabalin 150mg. Intra operative opioid 
requirement and postoperative pain score was reduced in both clonidine and 
pregabalin than placebo group but better reduction with clonidine. The sedation 
score was high in clonidine when compared to pregabaline and placebo. Post op 
drowsiness was more with clonidine than pregabalin and placebo. 
This study concluded that oral premedication with Clonidine200 µg and 
Pregabalin 150mg produces betterhemodynamic stability in laparoscopic 
surgeries but Clonidine produces better haemodynamic stability than 
Pregabalin.Both drugs has significantly reduces intraoperative and post operative 
analgesic requirements without significant post operative respiratory depression. 
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 PROFORMA 
COMPARISON OF EFFECTS OF ORAL CLONIDINE AND   PREGABALIN   
FOR HAEMODYNAMIC STABILITY    DURING LAPAROSCOPIC 
SURGERIES- A PROSPECTIVE RANDOMIZED PLACEBO CONTROL STUDY 
 
GROUP- 
NAME                                   AGE                   IP NO    WT     
PRE MED - Study drug / Placebo  
PRE INDUCTION  - Glycopyrrolate 0.2mg  & Midazolam- 0.03 mg/kg  
INDUCTION-  Propofol 2mg/kg  Fentanyl 2 mics/kg   Vecuronium 0.1mg/kg 
MAINTANANCE-  Oxygen:NitrousOxide 2:3  ,Vecuronium, Fentanyl -20mics half 
hrly (if additional analgesic required suppl with 10 mics)   
MONITORING  PARAMETERS 
 PR  SBP  DBP  MAP 
Base line    
 
    
Pre-op     
AI 1 Min     
AI  5 min      
AP 1 min      
AP 5 min      
AP 15 min      
AP 30 min      
AP 45 min     
PR      
AE       
 
REVERSAL- Neostigmine- 0.5mg/kg      
                   Glycopyrrolate- 0.01mg/kg  
Pain score:  Preop, AE, 1 Hr, 2 Hr, 4 Hr and 6 Hr. 
Sedation score: Preop, AE, 1 Hr, 2 Hr, 4Hr and 6 Hr. 
TOTAL FENTANYL REQUIREMENT -  
COMPLICATIONS – 
Nausea:   present / absent 
Vomiting:   present / absent 
Drowsiness:    present / absent 
  
Muha;r;rp xg;Gjy; gbtk; 
  yhg;gpuh];Nfhgp mWit rpfpr;irapd; NghJ ,jaj;Jbg;G kw;Wk; ,uj;j 
mOj;jj;jpy; Vw;gLk; khWjy;fis Clonidine kw;Wk; Pregabalin vd;w ,UNtW 
khj;jpiufis nfhz;L xg;gPLk; Ma;T. 
ngaH : 
taJ : 
,dk; : 
cs;Nehahsp vz;: 
thHL : 
Neha; : 
mWit rpfpr;ir : 
tpsf;fk;: 
 yhg;gpuh];Nfhgp mWit rpfpr;irapd; NghJ ,jaj; Jbg;G kw;Wk; ,uj;j 
mOj;jj;jpy; Vw;gLk; khWjy;fis Clonidine kw;Wk; Pregabalin vd;w ,UNtW 
khj;jpiufis kaf;f kUe;J nrYj;Jtjw;F rhpahf 1 kzp Neuj;jpw;F Kd;G 
tha; topahf cl;nfhs;tjhy; Vw;gLk; gyd;fs;> tpisTfs;> gf;f tpisTfs; 
gw;wp vdf;F ed;F Ghpfpd;w jkpo; nkhopapy; njspthf tpsf;fp $wg;gl;lJ. 
vd;Dila milahsk; ve;j tifapYk; ,e;j Muha;r;rp %yk; ntspNa njhpahJ 
vd;gij mwpNtd;. ,e;j Muha;r;rpapy; ,Ue;J ve;j NeuKk; tpyfyhk; vd;gijAk; 
mjdhy; ve;j ghjpg;Gk; Vw;glhJ vd;gijAk; mwpNtd;. 
 ehd; ahUila epHge;jkpd;wp vd; nrhe;j tpUg;gj;jpd; Nghpy; RaepidTld; 
,e;j Muha;r;rpapy; gq;F nfhs;s rk;kjpf;fpNwd;. 
,lk;:  
ehs;: ifnahg;gk; 
1 MIN 5 MIN
1 
MIN
5 
MIN
15 MIN
30 
MIN
45 
MIN
1 35 F 1 1 72 116 68 84 60 83 90 88 95 90 92 80 85 78 95
2 37 F 1 2 72 140 86 104 60 80 120 80 121 95 95 80 79 78 98
3 48 F 1 2 80 136 88 104 45 86 92 90 102 98 98 84 82 84 102
4 43 F 1 1 78 134 81 98 45 92 96 90 98 92 92 80 82 80 96
5 44 M 1 2 74 110 70 83 50 79 84 80 107 76 77 76 78 76 92
6 49 M 1 1 86 126 80 95 50 89 92 90 92 80 81 90 92 90 108
7 39 F 1 2 71 120 78 91 50 74 98 95 111 97 98 100 91 86 99
8 46 F 1 1 70 124 82 95 60 74 81 78 88 76 77 80 82 80 94
9 45 M 1 2 76 110 71 83 60 78 98 87 125 120 122 90 93 80 95
10 48 F 1 1 76 124 83 96 55 78 82 87 105 92 93 78 80 78 94
11 50 F 1 1 88 140 86 104 55 88 97 90 98 91 92 88 80 82 90
12 54 M 1 2 78 140 82 101 45 80 89 85 99 96 99 90 89 88 95
13 45 M 1 1 86 132 81 97 45 85 94 90 105 109 100 97 95 89 100
14 51 F 1 1 85 120 70 86 45 87 90 90 100 102 103 98 90 83 95
15 37 M 1 2 83 110 70 83 60 80 89 85 90 95 99 90 88 85 99
16 42 M 1 1 78 132 81 97 60 80 95 90 101 108 105 99 90 89 105
17 39 F 1 1 75 116 68 84 60 78 87 85 97 98 98 98 90 86 90
18 51 F 1 2 88 136 88 104 60 86 97 90 105 100 100 95 89 89 93
19 43 F 1 1 79 120 70 86 60 85 90 89 98 88 88 82 84 72 99
20 52 F 1 1 68 106 71 82 55 74 85 79 100 76 77 88 90 88 92
21 40 M 1 1 76 132 78 95 55 82 100 95 104 96 98 86 88 86 96
22 32 F 1 1 82 140 82 101 55 84 90 90 98 87 88 85 87 85 89
23 54 M 1 2 75 142 84 103 55 79 93 85 92 86 87 75 77 75 99
24 58 F 1 2 71 118 72 87 50 75 97 90 98 97 98 88 90 88 95
25 60 F 1 2 78 128 82 97 50 84 100 90 110 107 107 100 97 86 101
26 55 F 1 2 83 120 74 89 50 85 98 95 108 100 100 98 90 90 99
27 50 M 1 1 79 113 60 83 50 80 98 90 102 105 106 99 94 91 97
28 44 M 1 1 85 134 81 98 60 85 98 97 111 110 100 97 90 90 97
29 42 F 1 1 84 116 68 84 60 86 94 93 99 95 97 95 97 89 94
30 40 F 1 1 87 134 81 98 60 88 96 95 98 106 100 97 94 90 105
31 46 F 2 1 88 120 74 89 45 71 74 72 77 71 77 68 66 62 78
32 54 M 2 2 82 132 81 97 45 79 80 80 83 87 89 80 82 80 81
33 56 F 2 2 79 113 69 83 45 77 81 79 80 85 85 70 72 70 84
34 60 F 2 1 77 120 70 86 50 71 74 72 77 71 72 74 70 72 74
35 58 F 2 2 80 112 70 83 50 73 75 70 76 73 73 74 72 70 72
36 36 M 2 1 84 130 84 99 50 72 75 75 74 70 72 68 66 64 70
37 37 M 2 2 83 142 91 107 60 80 82 82 89 80 80 80 82 80 81
38 32 M 2 1 79 123 79 93 60 78 80 80 82 74 74 72 70 72 80
39 56 F 2 1 78 130 80 96 55 72 77 75 78 70 70 70 71 70 75
40 44 F 2 2 79 122 80 93 60 74 80 76 81 76 76 73 72 70 81
41 45 F 2 1 84 110 64 79 45 89 92 90 95 87 87 83 80 81 88
42 48 F 2 2 68 122 71 87 55 74 76 76 78 72 70 70 71 70 75
43 42 F 2 2 86 110 59 75 50 80 84 80 88 89 82 82 80 82 82
44 40 M 2 1 76 110 60 76 55 82 82 80 84 81 82 82 80 72 80
45 39 F 2 1 86 120 80 93 55 76 76 74 77 78 78 75 77 70 76
46 45 M 2 2 85 102 72 81 45 81 82 80 86 88 88 74 73 74 81
47 56 F 2 2 86 132 78 95 45 74 79 70 78 78 78 77 75 71 75
48 33 F 2 1 79 114 66 81 60 78 78 78 80 81 82 82 80 80 80
49 36 M 2 1 78 128 68 87 60 71 74 70 74 76 77 77 70 66 70
50 39 M 2 1 86 120 68 85 60 69 70 70 76 78 78 78 80 70 77
51 40 F 2 2 85 128 86 99 60 71 74 72 79 79 80 82 80 74 80
52 49 F 2 2 88 120 93 101 60 79 82 78 95 88 88 66 64 65 78
53 38 F 2 1 80 112 82 91 60 88 89 89 90 89 90 89 86 75 80
54 32 F 2 2 90 112 82 91 60 78 84 80 85 82 83 80 81 78 80
55 42 M 2 1 79 122 66 84 55 80 88 83 86 88 88 89 85 80 84
56 33 M 2 1 84 136 78 97 55 89 89 89 91 93 92 90 85 87 87
57 45 M 2 2 89 140 77 98 55 84 86 86 90 90 90 89 90 82 84
58 38 M 2 1 78 117 83 94 55 74 72 70 78 78 80 80 81 74 79
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59 60 F 2 2 84 110 76 87 45 82 84 84 88 87 89 90 90 88 88
60 44 F 2 1 86 129 91 102 45 68 70 70 77 77 78 80 82 80 80
61 52 M 3 1 78 124 80 94 60 78 80 80 88 88 89 86 80 78 88
62 49 M 3 2 76 119 77 91 55 75 81 80 101 100 99 95 85 80 90
63 58 M 3 1 88 114 75 88 55 86 90 85 92 92 94 89 90 82 92
64 50 F 3 2 86 123 86 98 45 92 94 94 98 98 96 90 94 89 97
65 52 F 3 1 84 116 74 88 45 86 89 85 98 92 93 90 89 88 90
66 40 M 3 2 76 132 80 97 50 81 84 84 90 92 90 92 90 87 99
67 44 F 3 2 70 122 82 95 50 76 79 78 80 82 84 80 82 80 88
68 37 F 3 2 60 126 84 98 50 64 64 65 78 78 80 80 78 80 88
69 58 M 3 2 74 130 80 96 60 79 82 80 88 86 86 85 80 78 90
70 55 F 3 1 73 130 78 95 60 78 82 80 86 88 90 90 87 85 85
71 57 F 3 2 83 124 78 93 60 80 98 90 107 109 110 103 98 82 100
72 43 F 3 2 68 108 70 82 60 71 76 76 79 100 102 82 81 80 85
73 44 F 3 2 76 110 76 87 55 74 88 80 89 92 92 88 87 80 95
74 42 F 3 1 71 121 78 92 55 76 80 79 90 92 94 96 88 84 94
75 46 M 3 2 78 129 84 99 50 82 87 85 90 97 99 100 94 88 102
76 38 F 3 1 64 130 82 98 45 71 90 90 100 102 100 100 98 90 99
77 32 F 3 2 70 126 84 98 45 75 89 80 110 110 108 105 109 89 98
78 38 F 3 1 68 122 81 94 45 79 82 82 95 90 92 94 88 85 91
79 36 M 3 1 71 116 68 84 60 78 78 75 80 82 84 82 85 87 95
80 58 F 3 1 80 112 71 84 60 88 82 80 90 93 96 93 90 88 103
81 55 M 3 2 86 124 80 94 55 80 93 90 100 102 100 102 98 90 98
82 57 M 3 1 90 130 80 96 55 88 88 85 90 92 94 97 90 88 89
83 49 M 3 1 86 110 76 87 60 86 87 85 90 90 92 93 92 87 89
84 43 F 3 1 86 116 68 84 60 84 90 90 100 102 104 104 99 90 101
85 38 F 3 1 80 110 70 83 50 82 83 80 88 89 90 90 85 86 88
86 36 F 3 2 87 136 88 104 50 80 85 85 90 95 95 95 90 84 90
87 41 M 3 2 88 120 78 91 45 79 80 80 81 89 87 89 82 82 84
88 35 F 3 1 79 110 71 83 45 81 90 82 96 102 100 105 99 91 107
89 32 F 3 1 85 126 80 95 50 83 85 82 88 89 90 89 90 81 83
90 52 M 3 2 88 134 81 98 60 85 89 80 89 88 87 91 84 85 88
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116 142 130 140 145 140 120 118 120 139 76 101 80 112 100 112 90 88 77 99
140 134 128 142 148 146 142 140 128 133 80 92 86 99 99 100 87 89 87 74
136 162 140 150 160 156 138 122 124 148 86 120 90 122 120 122 110 100 86 108
134 154 130 149 145 144 127 130 117 160 80 90 88 102 96 98 90 88 80 100
110 133 128 144 141 142 138 130 114 142 78 103 88 108 102 100 98 96 90 102
126 162 148 166 158 158 150 143 130 158 88 100 90 110 108 110 108 100 90 106
120 128 124 138 132 132 128 128 116 130 71 88 80 92 90 92 90 92 90 92
124 142 130 148 140 140 142 138 130 139 82 98 94 100 100 100 99 92 92 89
110 128 122 144 150 152 152 140 130 136 62 86 76 90 90 92 88 88 80 96
124 144 136 148 162 164 112 114 112 139 70 80 80 90 86 88 88 82 86 90
126 136 124 138 130 130 134 128 124 130 86 90 88 94 96 98 94 90 92 94
110 124 118 132 134 136 140 130 128 138 76 86 80 88 88 90 84 84 80 88
124 138 120 146 140 141 142 132 118 128 88 94 92 96 90 92 92 88 82 90
120 160 130 170 160 162 162 150 130 142 80 100 92 108 110 108 102 94 88 94
118 128 122 138 142 144 146 140 130 138 70 83 80 94 91 92 90 89 87 92
122 138 128 148 152 156 160 150 130 150 78 88 86 100 102 104 106 98 98 96
134 154 130 149 145 140 127 130 114 142 84 99 90 102 100 102 99 90 88 101
120 170 130 160 166 160 150 152 132 142 80 110 88 108 112 114 110 99 90 100
120 171 136 178 166 154 136 114 112 162 70 108 99 110 104 106 96 64 62 100
106 109 110 124 118 128 102 104 102 105 69 80 76 90 81 84 79 67 77 89
132 163 142 154 141 138 136 128 126 157 74 102 90 111 99 100 87 90 78 90
140 165 142 166 160 158 152 148 138 152 71 92 90 110 104 102 100 96 88 102
142 169 150 158 131 130 127 129 127 171 84 106 98 112 105 106 101 96 80 105
118 167 126 164 154 150 124 128 116 159 71 111 91 114 100 100 99 92 88 99
128 151 132 154 150 146 142 132 130 148 82 96 90 101 93 92 107 103 97 93
128 150 132 154 148 146 142 138 128 150 86 90 82 98 98 99 92 90 88 101
130 144 132 152 148 150 150 148 132 142 70 88 82 96 96 98 90 89 82 95
114 128 120 140 142 144 146 130 130 140 70 80 80 92 90 92 89 88 79 89
122 160 148 166 170 166 152 146 132 146 88 90 85 108 105 104 100 94 90 98
132 146 134 162 160 156 160 160 140 148 78 89 80 99 92 93 90 90 80 94
110 108 106 112 116 118 115 116 110 110 77 78 77 82 82 84 72 72 70 72
129 110 110 126 126 128 130 132 118 120 82 82 80 86 84 86 86 82 78 80
117 120 118 122 120 124 126 124 116 118 71 72 70 77 77 79 70 72 68 70
118 116 110 117 118 120 122 120 118 120 72 75 71 72 74 77 74 70 66 68
114 112 110 114 120 122 114 116 112 110 74 72 72 75 74 75 75 74 70 71
120 120 120 126 130 132 132 132 120 122 87 84 80 82 84 88 84 81 80 82
139 146 140 142 140 137 140 142 138 130 92 90 90 92 94 92 94 92 88 90
130 132 130 132 134 132 130 128 122 120 81 80 80 82 84 86 83 82 78 78
128 132 126 136 130 132 136 136 134 132 82 83 80 82 82 80 78 80 76 79
124 122 122 124 130 132 134 126 122 122 84 82 82 80 84 82 82 84 80 81
100 99 98 110 110 112 112 112 108 100 61 62 60 64 71 72 68 69 60 62
119 126 120 116 126 122 120 122 118 100 72 75 70 74 74 74 70 72 68 69
114 117 120 130 132 132 132 130 128 130 61 60 60 62 66 66 60 62 58 60
108 100 100 107 108 110 112 110 100 104 62 60 61 64 67 68 67 62 60 61
110 110 108 120 126 124 122 124 118 110 77 75 77 79 78 78 77 77 75 75
104 102 102 110 110 110 109 106 103 100 75 78 78 76 80 80 82 80 77 78
130 130 130 135 132 132 135 131 126 122 80 80 77 82 83 83 85 79 80 80
115 113 110 112 122 120 116 114 110 112 68 66 65 70 72 72 70 71 69 70
131 130 130 132 134 130 130 132 126 120 70 70 71 70 72 72 66 68 64 64
125 128 120 127 128 130 132 128 120 120 72 70 68 68 69 70 68 72 68 68
126 120 120 124 126 128 130 124 120 124 88 85 83 87 87 86 86 86 88 86
122 120 117 122 128 126 127 124 119 120 94 90 91 92 93 93 92 90 90 90
116 110 110 117 118 120 120 116 112 116 84 84 80 84 82 82 82 84 80 80
110 110 108 108 110 112 114 112 102 108 84 85 80 80 84 84 80 82 78 78
112 104 100 110 116 118 118 118 110 110 64 64 64 68 70 71 64 66 62 65
119 120 120 128 128 128 130 126 122 120 76 77 76 70 78 78 79 72 74 75
122 109 110 118 120 120 120 119 109 106 83 80 80 85 86 88 86 82 80 80
103 100 100 110 112 114 114 110 95 100 67 65 65 68 70 72 70 71 69 68
SYSTOLIC BLOOD PRESSURE DIASTOLIC BLOOD PRESSURE
P
R
E
O
P AI AP
PR AE
P
R
E
O
P AI AP
PR AE
S
.N
O
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
1 
MIN
5 
MIN
1 
MIN
 5 
MIN
15 
MIN
30 
MIN
45 
MIN
1 MIN
5 
MIN
1 
MIN
 5 
MIN
15 
MIN
30 
MIN
45 
MIN
SYSTOLIC BLOOD PRESSURE DIASTOLIC BLOOD PRESSURE
P
R
E
O
P AI AP
PR AE
P
R
E
O
P AI AP
PR AE
110 110 106 120 120 122 122 118 111 110 74 74 70 78 78 80 80 79 77 80
129 130 124 132 132 130 132 132 125 120 90 92 90 90 92 90 92 90 88 88
114 148 140 140 144 146 148 136 140 142 74 74 73 74 76 77 68 70 68 70
117 125 110 130 134 136 140 136 130 138 75 89 80 90 82 83 94 90 90 92
112 114 110 110 116 118 108 110 105 120 76 90 88 94 98 96 96 98 90 98
122 164 120 170 172 168 160 162 150 142 86 107 100 116 110 114 116 118 110 110
109 110 103 110 112 114 120 103 105 102 72 83 78 88 90 92 90 94 88 88
132 136 128 140 141 138 142 138 130 136 82 96 88 100 102 102 102 106 100 106
116 118 110 114 116 116 116 108 103 110 74 84 80 90 90 91 92 88 89 89
129 132 130 131 141 138 120 122 125 132 84 96 90 99 98 98 96 90 90 92
128 128 128 124 119 120 123 125 127 120 79 95 86 98 97 98 98 90 98 98
133 136 131 132 130 130 128 128 124 128 78 84 80 94 94 94 96 90 88 94
121 118 116 120 121 120 123 116 118 118 76 89 80 90 91 90 95 90 84 98
110 114 108 110 112 112 108 109 107 110 68 70 70 80 82 82 82 84 80 80
110 119 118 128 130 130 131 132 128 138 72 78 78 90 98 98 98 96 90 99
112 128 120 140 145 140 149 144 136 130 78 78 74 78 80 82 76 78 77 78
126 128 120 126 126 128 130 122 124 124 82 94 88 98 98 98 96 98 88 93
128 130 130 128 132 130 131 132 122 133 84 85 85 90 92 94 92 88 86 84
128 128 120 124 126 128 120 121 123 128 84 88 84 85 84 86 86 84 80 80
118 110 108 111 132 130 121 123 125 121 77 80 76 80 84 84 82 84 80 80
112 127 110 132 132 130 138 130 128 129 71 90 84 92 96 98 98 100 94 102
116 107 100 117 121 120 102 105 107 108 74 69 70 73 72 72 61 63 61 67
102 104 100 110 109 110 110 102 104 104 80 88 82 96 98 99 99 96 90 98
124 125 120 130 132 130 132 130 128 130 90 100 92 102 102 104 106 110 102 110
130 140 134 150 152 152 150 146 140 148 92 102 98 110 112 114 112 108 110 116
110 112 110 114 115 116 115 110 108 108 78 80 8 90 92 94 92 96 90 89
128 129 125 130 130 131 126 128 120 122 86 98 90 102 110 108 108 100 90 100
132 130 130 132 131 132 135 130 128 130 92 99 90 100 106 104 104 102 100 98
112 124 120 148 140 144 150 152 138 143 89 98 98 107 110 108 108 106 99 110
120 122 116 122 123 124 122 116 118 118 82 88 80 90 98 98 96 90 90 94
136 130 126 136 132 132 136 134 130 130 90 98 92 111 112 110 98 99 90 103
108 110 100 110 102 104 108 108 100 102 74 78 78 82 88 90 84 80 85 88
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89 115 97 121 115 121 100 98 91 112 2 5 6 6 5 6 1 1 1 1 2 2 150 A A A
100 106 100 113 115 115 105 106 101 94 2 5 6 7 6 5 1 2 2 2 1 1 140 A A A
103 134 107 131 133 133 119 107 99 121 1 4 5 6 6 6 1 1 2 1 1 2 160 A A A
98 111 102 118 112 113 102 102 92 120 2 4 5 6 6 6 1 1 1 2 1 1 150 A A A
89 113 101 120 115 114 111 107 98 115 1 5 6 7 6 6 1 1 2 1 2 2 160 A P A
101 121 109 129 125 126 122 114 103 123 1 5 5 6 5 5 1 1 1 2 1 1 160 A A A
87 101 95 107 104 105 103 104 99 105 1 5 5 7 6 6 1 2 2 1 2 2 150 A A A
96 113 106 116 113 113 113 107 105 106 2 6 6 7 6 5 1 2 1 2 2 1 140 A A A
78 100 91 108 110 112 109 105 97 109 2 5 5 6 6 6 1 1 1 1 2 2 170 A A A
88 101 99 109 111 113 96 93 95 106 2 5 5 7 6 6 1 1 2 2 2 1 200 A P P
99 105 100 109 107 109 107 103 103 106 1 6 6 7 7 7 1 2 2 2 2 2 100 A A A
87 99 93 103 103 105 103 99 96 105 1 6 5 6 6 6 1 2 2 2 2 2 120 A A A
100 109 101 113 107 108 109 103 94 103 2 6 6 7 7 7 1 3 3 2 2 2 100 A A A
93 120 105 129 127 126 122 113 102 110 2 7 6 6 5 6 1 1 2 2 2 2 150 P A A
86 98 94 109 108 109 109 106 101 107 1 5 5 6 6 6 1 1 1 1 2 2 150 A A P
93 105 100 116 119 121 124 115 109 114 1 6 5 6 5 5 1 1 1 2 2 2 120 A A A
101 117 103 118 115 115 108 103 97 115 2 5 5 5 6 6 1 3 3 2 2 2 140 A A A
93 130 102 125 130 129 123 117 104 114 1 6 7 7 6 6 1 1 2 2 2 2 140 A A A
87 129 111 133 125 122 109 81 79 121 1 6 5 6 6 6 1 1 1 1 2 2 160 A A A
81 90 87 101 93 99 87 79 85 94 1 5 6 7 6 5 1 1 2 1 2 2 160 A P A
93 122 107 125 113 113 103 103 94 112 2 5 6 6 6 6 1 1 1 1 2 1 170 A A A
94 116 107 129 123 121 117 113 105 119 1 5 6 7 6 6 1 1 1 1 2 2 160 P A A
103 127 115 127 114 114 110 107 96 127 2 5 6 6 6 6 1 1 1 2 1 2 200 A A A
87 130 103 131 118 117 107 104 97 119 1 5 6 7 6 6 1 2 2 2 1 2 180 A A A
97 114 104 119 112 110 119 113 108 111 1 5 6 7 6 6 1 1 1 2 1 1 190 A A A
100 110 99 117 115 115 109 106 101 117 2 5 6 6 7 6 1 3 3 2 2 2 100 P A A
90 107 99 115 113 115 110 109 99 111 2 6 7 7 5 5 1 1 1 1 2 2 120 A A A
85 96 93 108 107 109 108 102 96 106 1 4 6 6 5 6 1 1 2 2 2 2 120 A A A
99 113 106 127 127 125 117 111 104 114 2 5 5 5 5 5 1 3 3 2 2 2 120 A A P
96 108 98 120 115 114 113 113 100 112 1 4 5 5 6 6 1 1 1 2 2 2 150 A A A
88 88 87 92 93 95 86 87 83 85 0 1 2 3 2 3 2 3 3 3 3 3 10 A A A
98 91 90 99 98 100 101 99 91 93 0 1 2 2 3 3 2 3 4 3 3 3 10 A A A
86 88 86 92 91 94 89 89 84 86 1 2 2 3 2 2 3 2 4 2 3 2 20 A A A
87 89 84 87 89 91 90 87 83 85 1 1 2 3 3 3 2 2 3 3 3 3 20 A P P
87 85 85 88 89 91 88 88 84 84 1 2 2 2 2 2 2 3 4 3 3 3 40 A A P
98 96 93 97 99 103 100 98 93 95 1 1 2 2 2 3 2 2 3 3 3 3 40 A A A
108 109 107 109 109 107 109 109 105 103 1 2 2 3 3 2 2 3 4 3 3 3 30 A A P
97 97 97 99 101 101 99 97 93 92 0 1 2 2 2 3 2 2 3 3 3 2 30 A A P
97 99 95 100 98 97 97 99 95 97 1 2 2 2 2 2 2 3 4 3 2 3 30 P A A
97 95 95 95 99 99 99 98 94 95 0 1 2 2 2 3 2 3 4 3 3 3 20 A A A
74 74 73 79 84 85 83 83 76 75 0 2 2 2 2 3 3 3 3 2 3 3 20 A A A
88 92 87 88 91 90 87 89 85 79 1 1 2 2 3 3 2 2 3 3 3 3 30 P A A
79 79 80 85 88 88 84 85 81 83 1 2 2 3 2 3 2 3 4 2 3 2 40 A A P
77 73 74 78 81 82 82 78 73 75 0 1 2 2 2 2 3 3 3 3 3 3 20 A A P
88 87 87 93 94 93 92 93 89 87 0 2 1 2 2 3 3 2 4 3 3 2 20 A A A
85 86 86 87 90 90 91 89 86 85 0 2 1 3 3 2 2 3 3 2 2 2 30 P P A
97 97 95 100 99 99 102 96 95 94 1 1 3 3 3 3 3 3 4 3 3 3 20 A A P
84 82 80 84 89 88 85 85 83 84 1 2 3 2 2 3 2 2 4 3 3 2 20 A A A
90 90 91 91 93 91 87 89 85 83 1 2 2 2 2 3 2 3 3 3 3 3 40 A A P
90 89 85 88 89 90 89 91 85 85 1 1 2 3 3 2 3 3 3 3 3 3 30 A A P
101 97 95 99 100 100 101 99 99 99 1 1 2 2 2 2 2 3 3 3 3 3 20 P A A
103 100 100 102 105 104 104 101 100 100 1 1 2 2 2 2 2 3 4 3 3 3 20 A P P
95 93 90 95 94 95 95 95 91 92 1 2 2 3 3 2 3 2 4 3 3 3 20 A A P
93 93 89 89 93 93 91 92 86 88 1 1 2 2 2 2 3 2 4 3 3 3 20 A P A
80 77 76 82 85 87 82 83 78 80 1 2 2 3 2 2 2 3 3 2 3 2 10 P P A
90 91 91 89 95 95 96 90 90 90 1 3 3 3 2 3 3 2 4 3 3 3 60 A A P
96 90 90 96 97 99 97 94 90 89 2 3 3 3 2 2 2 3 3 4 4 4 50 A A A
79 77 77 82 84 86 85 84 78 79 1 3 3 3 2 2 2 2 4 3 3 3 60 A A A
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86 86 82 92 92 94 94 92 88 90 2 3 3 3 3 3 2 2 4 3 4 4 30 A A A
103 105 101 104 105 103 105 104 100 99 1 3 2 3 2 3 3 2 4 3 3 3 70 A A P
87 99 95 96 99 100 95 92 92 94 2 3 3 4 4 4 1 2 2 2 2 2 80 A A A
89 101 90 103 99 101 109 105 103 107 1 3 3 3 4 4 2 2 3 3 2 2 60 A A A
88 98 95 99 104 103 100 102 95 105 2 3 2 4 4 5 2 3 3 3 3 3 40 A A A
98 126 107 134 131 132 131 133 123 121 1 3 3 3 4 4 1 2 2 2 2 2 40 A P A
84 92 86 95 97 99 100 97 94 93 2 4 3 4 4 4 1 2 3 3 3 3 30 A A A
99 109 101 113 115 114 115 117 110 116 1 4 3 3 4 4 2 2 2 2 2 2 50 A A A
88 95 90 98 99 99 100 95 94 96 2 3 3 4 4 4 2 2 2 3 3 3 40 A A A
99 108 103 110 112 111 104 101 102 105 1 4 3 4 4 4 3 3 3 3 2 2 60 A A A
95 106 100 107 104 105 106 102 108 105 1 3 2 4 5 4 2 3 3 3 3 3 50 A A A
96 101 97 107 106 106 107 103 100 105 2 3 3 3 4 5 2 2 2 2 2 1 70 A A A
91 99 92 100 101 100 104 99 95 105 2 3 3 4 5 4 2 3 3 3 3 4 40 P A A
82 85 83 90 92 92 91 92 89 90 1 3 3 3 4 4 2 2 3 3 3 3 40 A A A
85 92 91 103 109 109 109 108 103 112 2 3 3 3 4 4 2 2 2 2 1 1 60 A A A
89 95 89 99 102 101 100 100 97 95 1 3 3 4 4 4 1 1 1 2 2 2 50 A A A
97 105 99 107 107 108 107 106 100 103 2 3 3 3 4 4 1 2 2 2 1 1 60 A A A
99 100 100 103 105 106 105 103 98 100 1 3 3 3 4 4 2 3 2 1 1 1 40 A A A
99 101 96 98 98 100 97 96 94 96 2 3 3 3 4 4 2 2 3 3 2 1 50 A A A
91 90 87 90 100 99 95 97 95 94 1 3 2 3 4 4 1 2 2 2 1 1 30 A A A
85 102 93 105 108 109 111 110 105 111 2 3 3 4 4 4 2 2 2 3 3 3 50 A A A
88 82 80 88 88 88 75 77 76 81 1 3 3 4 5 4 1 2 2 2 1 1 60 A A A
87 93 88 101 102 103 103 98 95 100 1 3 3 3 3 3 2 2 1 1 1 1 80 A A P
101 108 101 111 112 113 115 117 111 117 2 3 3 4 4 4 2 2 2 2 1 1 100 A A P
105 115 110 123 125 127 125 121 120 127 1 2 2 2 3 4 1 1 2 2 2 1 60 A P P
89 91 42 98 100 101 100 101 96 95 2 2 2 3 3 3 3 3 2 2 2 1 60 A A A
100 108 102 111 117 116 114 109 100 107 2 2 2 3 3 3 3 3 2 2 1 1 120 P P P
105 109 103 111 114 113 114 111 109 109 1 2 2 2 3 3 2 2 2 1 1 1 100 A A P
97 107 105 121 120 120 122 121 112 121 2 2 3 3 3 4 1 1 1 2 2 2 80 A A A
95 99 92 101 106 107 105 99 99 102 2 3 3 4 4 4 2 2 2 3 3 2 80 A A A
105 109 103 119 119 117 111 111 103 112 2 3 3 4 4 4 2 2 2 1 1 1 60 A A A
85 89 85 91 93 95 92 89 90 93 2 2 2 3 3 3 1 2 2 2 1 1 40 A A A
